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Abstract
Insulin replacement therapy is mostly used by patients with type 2 diabetes who become insulin deficient and have failed
other therapeutic options. They comprise about a quarter of those with diabetes, endures the majority of the complications
and consumes the majority of the resources. Adequate insulin replacement therapy can prevent complications and reduce
expenses, as long as therapy goals are achieved and maintained. Sadly, these therapy goals are seldom achieved and
outcomes have not improved for decades despite advances in pharmacotherapy and technology.
There is a growing recognition that the low success rate of insulin therapy results from intra-individual and inter-individual
variations in insulin requirements. Total insulin requirements per day vary considerably between patients and constantly
change without achieving a steady state. Thus, the key element in effective insulin therapy is unremitting and frequent
dosage adjustments that can overcome those dynamics. In practice, insulin adjustments are done sporadically during
outpatient clinic. Due to time constraints, providers are not able to deliver appropriate insulin dosage optimization.
The d-Nav® Insulin Guidance Service has been developed to provide appropriate insulinization in insulin users without
increasing the burden on healthcare systems. It relies on dedicated clinicians and a spectrum of technological solutions.
Patients are provided with a handheld device called d-Nav® which advises them what dose of insulin to administer during
each injection and automatically adjust insulin dosage when needed. The d-Nav care specialists periodically follow-up with
users through telephone calls and in-person consultations to bestow user confidence, correct usage errors, triage, and
identify uncharacteristic clinical courses.
The following review provide details about the service and its clinical outcomes.
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Background
Index cases
Ms. R. is a 69-year-old woman with type 2 diabetes who
has been treated with insulin since 2011. She is currently
treated with basal-bolus insulin therapy that consists of
once daily long-acting insulin analog and 3 rapid-acting
insulin analog boluses with meals. Her diabetes control
was poor for years, and in 4/2013 her A1c was 9.8%.
Since 7/2014, her glycemic control has improved consid-
erably with A1c levels ranging between 6.9% and 7.7%.
She typically measures glucose 4 times/day before all
meals and before bedtime. The frequency of her re-
corded hypoglycemia (glucose < 60 mg/dl) has been low
at about 0.5 events per week without any nocturnal
events. To achieve good glycemic control on insulin
therapy, her insulin dosage has been adjusted 48 times
over the past 28 weeks (see details in Fig. 1a). Notably,
her total daily insulin was increased by about 15% for a
period of 5 months before it decreased to the original
daily insulin dosage. Most of her dosage changes oc-
curred in her long-acting insulin dose and her dinner
rapid-acting insulin dose, although other components
have changed as well.
Mr. E. is a 61-year-old man with type 2 diabetes who
has been treated with insulin for 20 years. He is
currently treated with basal-bolus insulin therapy. His
diabetes control was poor for years and in 8/2015 his
A1c was 9.1%. Since 11/2015, his glycemic control has
improved considerably with A1c levels ranging between
5.5% to 6.6%. Lately, he has been measuring glucose
about 23 times per week, regularly skipping pre-dinner
tests. The frequency of his recorded hypoglycemia
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Fig. 1 d-Nav downloads for the index patients. The upper graph denotes total daily insulin over time. The lower graph denotes each component of
the patient dosage, including long-acting insulin analog before bed and rapid-acting insulin analog with breakfast, lunch and dinner. Correction
factors are not shown. a) Ms. R.; b) Mr. E
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(glucose < 60 mg/dl) has been low at 0.2 events per week
with a single nocturnal event for the past year. To
achieve good glycemic control on insulin therapy, his in-
sulin dosage has been adjusted 49 times over the past
32 weeks (see details in Fig. 1b). Between the beginning
of 2017 and 6/2017, his insulin requirements and hence
total daily insulin gradually increased by about 60% until
it steadied in the beginning of 6/2017. Despite this rela-
tive stability in total daily insulin requirement, each
component of his therapy continued to change. For ex-
ample, dinner rapid-acting insulin bolus decreased by
about 20%, breakfast increased by about 7% and long-
acting insulin decreased by about 35%.
Ms. S. is a 62-year-old woman with type 2 diabetes
who has been treated with insulin for 15 years. She is
currently treated with basal-bolus insulin therapy. Her
diabetes control was inadequate for years and in 2/2013
her A1c was 11.7%. Since 7/2013, her glycemic control
has improved considerably with A1c levels ranging
between 6.8% to 7.6%. Lately, she has been measuring
glucose about 20 times per week, missing about a third
of the times before lunch and bedtime. In 11/2015, her
insulin requirements decreased by about 40% over a
period of 2 weeks without warning or clear clinical
reason. This reduction occurred mainly in her long-
acting insulin dosage component, and to some extent in
her lunch and breakfast boluses. After this noteworthy
dosage reduction occurred, the frequency of her re-
corded hypoglycemia (glucose < 60 mg/dl) has been low
at 0.7 events per week without any nocturnal events. To
achieve good glycemic control on insulin therapy, her
insulin dosage has been adjusted 50 times over the past
30 weeks (see details in Fig. 2c).
The above examples represent 3 typical patients with
type 2 diabetes who use insulin. They have required con-
siderable clinical effort in insulin titrations to improve
and maintain appropriate diabetes control. In reality,
most specialized providers are expected to provide care
for hundreds of patients using insulin. Is it realistic to
expect healthcare professionals to provide such a level of
care to their patients?
In fact, the 3 examples are patients whose insulin ther-
apy has been managed by the d-Nav® Insulin Guidance
Service. The providers who referred these patients to the
service had the ability to supervise the process but were
not involved in the process of insulin dosage titration.
Fig. 2 The graph denotes weekly mean glucose (in mg/dl). Episodes of minor daytime hypoglycemia are shown in the lower graph as red dots
(glucose < 60 mg/dl). Nocturnal events are shown as blue stars. c) Ms. S
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The “insulin paradox”
Patients with hormonal deficiencies are commonly seen in
endocrinology practices. The endocrinologist is expected
not only to diagnose the deficiency but also to fully re-
place it with adequate dosage of the appropriate hormone.
Fundamentally, Inappropriate hormonal replacements
such as hypothyroidism, adrenal insufficiency, or hypo-
gonadism are considered as clinically unacceptable and
poor quality-markers for the clinician. In contrast, re-
placement of the most common hormone deficiency,
namely insulin deficiency (i.e., diabetes), is ineffective in
the majority of the cases, even in the most reputable
clinics and predominantly blamed on the patient.
Insulin replacement therapy is mostly used by patients
with type 2 diabetes who become insulin deficient and have
failed other therapeutic options (herein referred to as ad-
vanced diabetes). During the first decade with the disease,
oral or non-insulin injectable medications that enhance en-
dogenous insulin secretion and alleviate its resistance [1–4],
are mostly suitable and effective in maintaining adequate
glycemia. The clinical picture changes typically toward the
second decade, during which many patients progress their
insulin deficiency to the extent that insulin replacement
therapy is warranted [5]. Initially, many patients can do well
with simple regimens such as long-acting insulin only, yet
over a period of a few years most require some level of fast
acting insulin coverage to maintain appropriate glycemia
[6]. About a quarter of the patients with type 2 diabetes use
insulin. This cohort endures the majority of the complica-
tions and consumes the majority of the resources [7].
Although insulin as a hormone possesses multiple
metabolic functions [8], the main therapeutic marker
used to assess therapy adequacy is average glucose, or
glycated hemoglobin (A1c). Studies have shown that ad-
equate insulin replacement therapy prevents complica-
tions and premature death as long as therapy goals are
achieved and maintained [9, 10]. Undoubtedly, supervi-
sion of statins and maintenance of normal blood pres-
sure are vital [11]. The importance in reassuring
appropriate insulin availability transpires beyond pre-
venting glycemic damage [12]. Emerging data has shown
that loss of insulin signaling in critical organs, worsens
atherosclerosis and nephropathy in normoglycemic ani-
mals [13–15].
Most authorities recommend an A1c goal between 6.5%
(and even lower if feasible) to 7.5% for the majority of pa-
tients [16–18]. Sadly, these therapy goals are seldom
achieved and outcomes have not improved for decades des-
pite advances in pharmacotherapy and technology. The
average A1c in insulin users in the USA (as in Europe) is
approximately 8.5% and a third of users continue to experi-
ence A1c at 9% or higher [19–21].
This phenomenon (also called the “insulin paradox”) is
peculiar given the benefit of the drug and its safety
profile. Insulin has been available for almost a century
and exists in a variety of formulations with different
pharmacokinetic and pharmacodynamic profiles. Com-
pared to all other diabetes drugs, insulin does not have
an upper dosage limit, and therefore, there is no level of
hyperglycemia it cannot overcome. The only consider-
able side effect related to insulin therapy is
hypoglycemia. It is the only known side effect that has
been shown to be directly related to insulin and may be
hazardous [22, 23]. Hypoglycemia has been experienced by
most patients with insulin and it is the main limiting factor
for effective insulin therapy. Severe hypoglycemia is the
main aspect of hypoglycemia that has been feared by pa-
tients and clinicians alike. Tremendous amount of research
has been made to understand and prevent these severe
events [24, 25]. Intriguingly, in prospective clinical studies,
for each individual who dies of severe hypoglycemia, hun-
dreds die from other conditions of which many are related
to diabetes and may potentially be preventable [26, 27].
Administration of insulin is largely painless, and the
level of patient compliance is not different from compli-
ance with other medications used to treat diabetes or
other medical conditions such as hypertension [28–30].
It has been shown that about a quarter of patients with
chronic medical conditions (including diabetes) do not
follow providers’ recommendations [28]. Therefore, lim-
ited compliance doesn’t explain why most patients using
insulin do not achieve their therapy goals.
There is a growing recognition that the “insulin para-
dox” results from intra-individual and inter-individual
variations in insulin requirements. Normal pancreases
secrete about 1 unit of insulin per kg body weight per
day [31–34]. Endogenous pancreatic insulin secretion
occurs in the portal system; whereas, the main organ re-
sponsive to the hormone is the liver. Under physiological
settings, the liver retains about 85% of the digested glu-
cose [31]. Once a patient loses their ability to secret
enough insulin and requires insulin replacement therapy,
the insulin is administered peripherally, outside the por-
tal system. Due to peripheral metabolism of the hor-
mone, mainly in the kidney, the required dosage needed
to achieve similar levels of insulin in the portal system
doubles [35]. This does not take into account cutaneous
degradation of injected insulin that has been found to be
considerable in some patients [36]. Endogenous insulin
resources likely diminish gradually, as it may take a few
years to build the required individual daily dosage once
insulin therapy is initiated [6]. Although patients gain
about 5 kg with insulin initiation, this weight gain plat-
eaus within a year and therefore does not explain the
gradual increase in insulin requirements that can last as
long as 3 years [6]. In the majority of cases patients’ fluc-
tuations in blood glucose and their tendency to develop
hypoglycemia worsens after a few years [37]. Not
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surprisingly, in clinical studies that supervise treat-to-
target insulin therapy in patients with type 2 diabetes,
individual daily requirements average at 1.5–2 units per
kilogram with a wide variance of distribution [38, 39].
Some patients use more than 500 units per day and oc-
casionally utilize concentrated insulin formulations [40].
Importantly, higher dosage of insulin per day has not
been shown to be associated with increased risk of
hypoglycemia [41].
Insulin needs do not reach a steady state in patients
with either type 1 or type 2 diabetes, as shown in the
index cases in this review (Figs. 1 and 2). The need to
constantly titrate insulin dosage in order to maintain
euglycemia was demonstrated in clinical studies which
supervised frequent insulin titrations both in the context
of type 1 [42, 43] and type 2 diabetes [39, 44–51]. For
most patients, insulin needs are unpredictable and dy-
namic, with requirements changing by 40% or even
more (Fig. 3) [52, 54]. Unpredicted changes in insulin re-
quirements expose patients to hypoglycemia or hyper-
glycemia [52–54].
Consequently, the key element in effective insulin
therapy is unremitting and frequent dosage adjustments
that can overcome those dynamics and enable mainten-
ance of optimal glycemic control while minimizing oc-
currences of hypoglycemia [50, 53–56]. Judging from
commonly used titration protocols, weekly titrations are
preferable [39, 50, 51]. Simply stated, insulin is likely one
the most dynamic drug existing in modern medicine.
Not surprisingly, A1c goals have been achieved and main-
tained primarily in clinical trials that implement insulin
dosage adjustment every few days-weeks [39, 44–51]. This
beneficial effect lasts only as long as periodic adjustments
are made by the medical staff, evidenced by deterioration
of glycemic control within a few months after the studies
end and insulin titrations became more sporadic [57, 58].
In practice, insulin adjustments are done sporadically dur-
ing outpatient clinic visits every 3–6 months, which ex-
plains why the effectiveness of one of the earliest and
most promising drugs in modern medicine has largely
been poor. Patients are not typically blamed for inad-
equate blood pressure management or persistent elevated
LDL, nor should they be blamed for inadequate insulin re-
placement therapy.
Insulin dosage titration is a teachable skill, yet it is time
consuming and requires resources that are only available
in well-funded trials. For illustration, it may take more
than 15 min to contact a patient, deliberate, and convey
adjustment in dosage. Even if a provider did nothing else
but adjust weekly insulin dosage, he/she would only be
able to support about 150 patients each. In the USA, there
are about 7,000,000 patients who use insulin
(www.cdc.gov/diabetes/statistics/meduse/fig2.htm). Thus,
over 44,000 providers dedicated only to insulin dosage
adjustments would be required to effectively support pa-
tients via means such as telemedicine. Currently, in the
USA, there are about 15,000 providers who possess the re-
quired expertise [59] (https://www.diabeteseducator.org/
about-aade), yet their time is already fully committed.
Even every-other-week insulin dosage adjustments would
overwhelm the healthcare system. Most importantly, the
challenge is not in the collection and delivery of glucose
data to the provider, for which a breadth of advanced
technological solutions is available. It is not even in the
deliberation process and medical decision-making. The
main challenge is the need to close the loop; to deliver the
recommendation to the patient in a way that he/she un-
derstands and can comfortably incorporate into daily life
until the next adjustment is needed.
The prevalence of type 2 diabetes is on the rise; how-
ever, the availability of providers with expertise in insulin
therapy is globally stable and low. As mentioned above,
due to time constraints, providers are not able to deliver
appropriate insulin dosage optimization. Accordingly,
the only solution to the problem is one that provides fre-
quent insulin dosage titrations in a way that the success
of the therapy does not increase the burden on health
care systems.
The d-Nav® insulin guidance service
Hygieia, Inc. was spun out of the University of Michigan
and founded in 2008 by Israel Hodish, MD, PhD and
Eran Bashan, PhD. The company has developed a scalable
solution to the problem in the form of an integrated service
that provides appropriate insulinization in insulin users.
The service relies on dedicated clinicians (also called d-Nav
Care Specialists) who utilize a spectrum of proprietary
technological solutions. The integrated care service model
follows existing models such as: dialysis services (e.g.,
www.davita.com), imaging services (e.g., www.flatworldso-
lutions.com), home infusion (e.g., www.infusionoptions.net/
index.html), physical therapy, etc.
Patients referred to the service, are provided with a
handheld device called d-Nav (stands for diabetes navi-
gator) which advises them what dose of insulin to ad-
minister during each injection. This simple to use device
is CE-marked and used by patients to monitor their glu-
cose level before each injection (not yet approved by the
FDA). In turn, it provides a recommended insulin dose.
Following the logic of diabetes specialists and concordant
with the gold standard guidelines for insulin management
[60], the device assesses the patient’s response to its
current insulin dosage by analyzing glucose patterns on a
weekly basis (glucose readings from the on board sensor
are stored in the device), then automatically adjusts the
user’s insulin dosage [53, 54, 61, 62]. The device does not
require any behavioral changes from the user. Adjustments
are typically made weekly. Yet, if insulin requirements drop
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Fig. 3 Decline in insulin requirements over time (≥25% of prior dosage) in patients with type 2 diabetes using the d-Nav Insulin Guidance Service.
a) Histogram depicting frequency of dosage reduction per year. In half of the cases, events occurred more than 0.6 times per year. b) Histogram
depicting percentage of dosage reduction. In half of the cases, total daily insulin dosage decreased by more than 37.8%. c) Histogram depicting
duration of decrease in insulin needs. In half of the cases, duration of the period exceeded 8.4 weeks. The graphs were reproduced from an
already published information; Harper et al. [52]
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or hypoglycemia ensues, d-Nav makes immediate adjust-
ments as often as needed, following the safety-first ap-
proach. This dynamic insulin therapy, first closes the gap
between the initial prescribed total daily dose and the thera-
peutic one and then constantly evaluates each component
of the therapy to fit the patient’s changing needs while pre-
venting an increase in hypoglycemia. Since d-Nav provides
insulin dose recommendations it is typically used before
every insulin injection, i.e., from one to four times a day de-
pending on the regimen. d-Nav adjusts most types of insu-
lin regimens: A) once a day basal insulin; B) twice daily
biphasic/premixed long- and short-acting insulin; and, C)
intensive insulin therapy involving long-acting and fast-
acting insulin with or without carbohydrate counting [62].
The d-Nav care specialists periodically follow-up with
users through telephone calls and in-person consulta-
tions to bestow user confidence, correct usage errors,
triage, and identify uncharacteristic clinical courses (ex-
ample in Fig. 2c). The d-Nav care specialist team uses
software solutions that analyze a device’s data to identify
usage errors and recognize atypical clinical courses. For
example, the software tools help to recognize if a patient
requires a different insulin regimen, such as biphasic in-
sulin therapy instead of basal insulin only [53, 63]. These
software tools are available for providers during and be-
tween clinic visits. The service is linked to a wider
healthcare system such that a patient’s data is always
available to be reviewed by the patient’s physicians.
Clinical outcomes and safety
During the time this review was written, 1253 patients have
been referred to the d-Nav service for an accumulated
period of 1847 patient years. Most patients were referred
with type 2 diabetes. Among active users, 339 have used
the d-Nav service for more than 2 years. To date, patients’
average (±standard deviation) age is 60.8 ± 10.3 years, aver-
age duration of diabetes 15.8 ± 7.9 years and average dur-
ation of insulin usage 9.4 ± 7.5 years. Reduction in A1c is
observed within 3 months of patients’ starting the d-Nav
service. Most patients achieved and maintained glycemic
goals for as long as they stayed with the service (Fig. 4).
About 20% of the patients withdraw during the first year
and less than 10% per year withdraw thereafter.
During the time this review was written, the frequency
of severe hypoglycemia has been 2.2 per 100 patient years
(in a cohort including patients with both type 2 and type 1
diabetes). For comparison, the expected frequency of
severe hypoglycemia in insulin users with type 2 diabetes
is 4–5 events per 100 patient years [25, 64]. In patients
with type 1 diabetes, the frequency is higher [37].
Cost saving
Diabetes is one of the priciest conditions to manage and its
demands are on the rise. As of 2012, the estimated US
expenditure for diabetes care was $245 Billion [65]. Pa-
tients with advanced diabetes, who are more likely to re-
quire insulin therapy, consume the majority of the
resources.
We believe that cost saving can be realized in 3 differ-
ent areas: reductions in complications and hospitaliza-
tions; reductions in outpatient clinic costs; and,
reductions in pharmaceutical expenses. While the first 2
categories may require a few years of improved patients’
glycemia in order to show cost savings, the last category
may exert its savings within a few months.
It has been estimated that improved glycemic control
can reduce cost, mainly due to reduction in hospital ad-
missions [66] and enhancement in the healing of foot ul-
cers [67, 68]. The latter has been estimated to be
prevalent in up to 25% of patients with diabetes [69]. A
health-economic model evaluating the cost effectiveness
of the d-Nav insulin guidance service in the United
Kingdom projected savings of £1459 per patient over a
3-year period in all patients, and £4992 per patient over
a 3-year period in high risk patients [68].
It has been suggested that about half of the insulin
treated patients with type 2 diabetes tend to have monthly
physician visits [70], likely due to high frequency of com-
plications [67]. This can potentially be alleviated within
the first few years of glycemic improvement.
Most authorities consider effective insulin therapy
alongside metformin to be an adequate antidiabetic regi-
men [17, 60]. Yet, since most patients using insulin fail
to achieve adequate glycemia, other anti-hyperglycemics
are typically co-prescribed, some of which are branded
and expensive. This polypharmacy increases costs and
the risk for side effects, and may not achieve therapy
goals [71, 72]. Although some prognostic benefit has
been implicated with non-insulin anti-hyperglycemics
[73–76], given the prognostic implications of successful
insulin therapy [9], it is not entirely clear that other
pharmacotherapy is needed if insulin therapy is effective.
In a health economic evaluation, 217 patients were en-
rolled in to the d-Nav Insulin Guidance Service through
a participating insurance group. In the 192 patients who
completed the first 90 days of follow up, projected direct
savings from medication elimination was estimated at
$1736 per patient per year for all patients, and a pro-
jected saving of $6172 per patient per year for patient
who used branded medications [77].
Competing solutions
The d-Nav Insulin Guidance Service provides insulin
management, yet it by no means competes with primary
care or endocrine services. Those are absolutely critical
for the holistic management of the patients who often
experience comorbidities and complications. There are
currently 4 categories of alternative approaches for the
Hodish Clinical Diabetes and Endocrinology  (2018) 4:8 Page 7 of 11
purpose of insulin therapy optimization: data delivery
platforms, insulin dose calculators, decision support sys-
tems and closed loop insulin delivery devices.
Data delivery platforms
As digital communication technology is advancing; a
multitude of data delivery systems are becoming avail-
able. They enable real-time delivery of glucose readings
from patients’ glucose monitoring devices to their physi-
cians (e.g., http://telcare.com, https://www.livongo.com,
Accu-Check® [78]). With telemedicine, physicians and
their staff can talk to patients face-to-face (e.g., https://
evisit.com) to provide as many medications adjustments
as they see fit. However, the rate-limiting factor is the
large number of patients and the frequency of dosage
adjustments that they need. Therefore, data delivery
platforms are unlikely to provide a solution for insulin
therapy.
Dose calculators
A breadth of titration guidelines has been used by stud-
ies who supervised insulin therapy and some were com-
pared [39, 79]. The similarity in success rates and the
minor differences between them [49], implies that a key
element in their respective success is likely related to the
frequency in which they were applied. Many of the titra-
tion guidelines have been transformed into commercially
available tools or apps of which some are FDA approved
(e.g., https://isageapp.com, http://voluntis.com, My Dose
Coach from Sanofi-Aventis). Apps can be used by pa-
tients and can enable patients to titrate their own insulin
dosage with their phone. However, these apps currently
require the prescribing provider to select or design an
appropriate titration algorithm for each patient and to
assume full responsibility for the process of dose
titration. Accordingly, they still significantly increase the
burden of prescribing providers.
Decision support systems
The process of insulin dosage titration is better managed
if expertise is available. On the other hand, the number of
providers who are versed in managing insulin therapy is
limited and not expected to grow significantly. Existing so-
lutions including decision support for insulin titration that
can be accessed by providers (e.g., www.insulinalgorit
hms.com, http://www.glytecsystems.com). However, such
solutions still leave the burden of conveying the new dos-
age to the patients on the providers side. As mentioned
above, we believe that any solution that increase providers’
workload is unlikely to be successful due to the limited
available time of healthcare providers.
Closed loop insulin delivery devices or artificial pancreas
A great deal of research have been invested to develop a
closed loop system combing an insulin pump and a con-
tinuous glucose monitor to form an “artificial pancreas
[80].” These systems can continuously adjust ongoing in-
sulin delivery based on prevailing glucose (www.medtro
nicdiabetes.com). The main impediments to this ap-
proach is complexity. Although insulin pumps were first
available in the 1980s, they are currently used by about
50% of individuals with type 1 diabetes in the US [81]
and by only about 1 million users globally [82]. Continu-
ous glucose monitor devices (CGM) were introduced
over a decade ago and are currently used by a few
hundred-thousand patients (e.g., Dexcom about 200,000
globally in 2016, http://investor.shareholder.com/dex
com/releasedetail.cfm?ReleaseID=1014972).
Currently, the main users of these systems are patients
with type 1 diabetes. This chronic condition is hard on
Fig. 4 Average A1c in d-Nav users in Europe who have been in the service for more the 3 months
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patients and providers alike, but relatively uncommon.
Among patients with type 1 diabetes, many have stopped
using either devices due to their complexity and intense
requirements. It is not clear that the 7,000,000 insulin
users with type 2 diabetes in the US, who are generally
older than the average insulin user with type 1 diabetes,
would be willing to adopt the complexity of using an in-
sulin pump and a CGM.
Proof of concept
Whatever solution used to improve the care of patients
using insulin, enhanced clinical outcomes and reduced
cost can only be realized if clinical goals are actually
achieved. Hence, proof of concept is critical. It should
demonstrate not only efficacy and safety in short-term
clinical trials, but also durable effect in real-life over a
long period of time.
Conclusion
Despite insulin’s long-term availability and still disappoint-
ing outcomes, we believe that achieving glycemic goals in
insulin users with type 2 diabetes is within reach. When
provided with frequent titration to optimize insulin dos-
age, the majority of patients using insulin could be main-
tained in a good quality of life for a longer time, while
saving health care system resources.
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